420 with CWN — Four Recent Medical Marijuana Stu
Post# of 277
(Total Views: 180)
Posted On: 08/22/2022 5:11:19 PM
420 with CWN — Four Recent Medical Marijuana Studies Worth Knowing About
A significant amount of research has been conducted in the medical marijuana field these last few years, revealing much about how the drug can be used in the management of various conditions. Below is an outline of some new studies on the use of cannabis and cannabis compounds, such as CBD, in the treatment of various conditions, including multiple sclerosis, coronavirus and fibromyalgia.
Use of CBD as potential coronavirus treatment
Figures from the World Health Organization (WHO) show that the coronavirus has caused more than 6.4 million deaths and over the last two years.
A recently conducted literature review assessed studies that tested the use of CBD to manage inflammation caused by the coronavirus. Preclinical medical marijuana studies showed promise for the compound’s impact on inflammatory outcomes of the cornea, gastrointestinal tract and lungs.
However, the authors stated in their conclusion that there wasn’t enough evidence to refute or support CBD as a repurpose medication for the treatment of inflammation and other coronavirus symptoms. They added that more clinical trials were needed to test CBD’s effectiveness.
Use of medical marijuana in managing fibromyalgia pain
Researchers from McGill University, Rutgers, Canopy Growth Corp. and the University of Montreal have assessed the potential mechanisms underlying a decrease in pain among patients with fibromyalgia who use medical marijuana.
The scientists stated that their analyses demonstrated that a decrease in levels of pain in patients could partly be explained by synchronous reductions in negative affect and sleep problems.
In their conclusion, the researchers stated that their findings showed decreases in pain, but this couldn’t be generalized to all patients with fibromyalgia who were using medical marijuana.
Impact of CBD on nerve cells in the brain
Researchers from the University of Milan collaborated with Curaleaf and Imperial College London’s Mikael Sodergren to assess CBD’s potential in treating neurodegenerative and psychiatric disorders.
The researchers focused on the brain-derived neurotrophic factor (BDNF) gene, finding that CBD could regulate the expression of this gene. Low levels of this gene, which promotes nerve cell maturation and growth, have been linked to epilepsy, Alzheimer’s, depression and schizophrenia.
Promising findings for CBD in treating multiple sclerosis
Multiple sclerosis is a chronic neurodegenerative and inflammatory illness of the central nervous system. Common symptoms of this disease include cognitive, motor, sensory and affective disturbances. New data shows that more and more patients with this illness are beginning to use cannabis-based medicinal products to manage their symptoms.
The researchers who conducted the study argue that there are promising indications for the use of cannabis-based medicinal products in the symptomatic treatment of multiple sclerosis.
It is worth noting that many people buy and use products from licensed companies such as Flora Growth Corp. (NASDAQ: FLGC) to obtain relief from a variety of disease symptoms, so it would be beneficial if researchers also studied and provided definitive guidance on the other conditions for which people say they use cannabis.
NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
A significant amount of research has been conducted in the medical marijuana field these last few years, revealing much about how the drug can be used in the management of various conditions. Below is an outline of some new studies on the use of cannabis and cannabis compounds, such as CBD, in the treatment of various conditions, including multiple sclerosis, coronavirus and fibromyalgia.
Use of CBD as potential coronavirus treatment
Figures from the World Health Organization (WHO) show that the coronavirus has caused more than 6.4 million deaths and over the last two years.
A recently conducted literature review assessed studies that tested the use of CBD to manage inflammation caused by the coronavirus. Preclinical medical marijuana studies showed promise for the compound’s impact on inflammatory outcomes of the cornea, gastrointestinal tract and lungs.
However, the authors stated in their conclusion that there wasn’t enough evidence to refute or support CBD as a repurpose medication for the treatment of inflammation and other coronavirus symptoms. They added that more clinical trials were needed to test CBD’s effectiveness.
Use of medical marijuana in managing fibromyalgia pain
Researchers from McGill University, Rutgers, Canopy Growth Corp. and the University of Montreal have assessed the potential mechanisms underlying a decrease in pain among patients with fibromyalgia who use medical marijuana.
The scientists stated that their analyses demonstrated that a decrease in levels of pain in patients could partly be explained by synchronous reductions in negative affect and sleep problems.
In their conclusion, the researchers stated that their findings showed decreases in pain, but this couldn’t be generalized to all patients with fibromyalgia who were using medical marijuana.
Impact of CBD on nerve cells in the brain
Researchers from the University of Milan collaborated with Curaleaf and Imperial College London’s Mikael Sodergren to assess CBD’s potential in treating neurodegenerative and psychiatric disorders.
The researchers focused on the brain-derived neurotrophic factor (BDNF) gene, finding that CBD could regulate the expression of this gene. Low levels of this gene, which promotes nerve cell maturation and growth, have been linked to epilepsy, Alzheimer’s, depression and schizophrenia.
Promising findings for CBD in treating multiple sclerosis
Multiple sclerosis is a chronic neurodegenerative and inflammatory illness of the central nervous system. Common symptoms of this disease include cognitive, motor, sensory and affective disturbances. New data shows that more and more patients with this illness are beginning to use cannabis-based medicinal products to manage their symptoms.
The researchers who conducted the study argue that there are promising indications for the use of cannabis-based medicinal products in the symptomatic treatment of multiple sclerosis.
It is worth noting that many people buy and use products from licensed companies such as Flora Growth Corp. (NASDAQ: FLGC) to obtain relief from a variety of disease symptoms, so it would be beneficial if researchers also studied and provided definitive guidance on the other conditions for which people say they use cannabis.
NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
(0)
(0)Flora Growth Corp. (FLGC) Stock Research Links
Scroll down for more posts ▼